T-DM1 after incomplete response to initial breast cancer therapy
Part of Cancer, Skin clinical trials.
This trial is for people with HER2-positive breast cancer who still had cancer after initial chemotherapy. It tests the safety and effectiveness of a drug called T-DM1 (Kadcyla) given after surgery to reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HER2-positive breast cancer (a type of breast cancer that is positive for a protein called HER2).
- After your initial chemotherapy (which included an anti-HER2 drug), you still had some cancer left in your breast or lymph nodes when your doctor checked.
- Your doctor plans to give you a medicine called T-DM1 (Kadcyla) after surgery, along with hormone therapy if your cancer is hormone-receptor-positive.
- You have not had another type of cancer in the past.
- You do not have any medical reason that would make it unsafe to take T-DM1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a standard follow-up treatment plan that combines chemotherapy and radiation after surgery, and it looks for blood/tissue “biomarkers” that predict who benefits most. If you have high-risk breast cancer that didn’t fully disappear after initial (neoadjuvant) chemo, you may be eligible to help guide better future treatment choices.
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
This trial compares a new drug called Trastuzumab-Deruxtecan (T-DXd) to standard treatment for people with early breast cancer whose cancer has come back at a molecular level (detected by a blood test) but hasn't spread to other parts of the body. The goal is to see if T-DXd can prevent the cancer from returning.
This study follows women with advanced breast cancer (metastatic) who have hormone-receptor positive tumors and low HER2 levels, to see how well a new drug called Trastuzumab Deruxtecan works when used in routine clinical care after prior hormone therapy.
This study looks at how well Trastuzumab Deruxtecan (T-DXd) works in Chinese women with breast cancer that has spread. It is for people whose cancer is either HER2-positive or HER2-low and who have already had some treatment.
This trial looks at whether a different targeted therapy, T-DM1, can work for women with advanced HER2-positive breast cancer after they have already tried another targeted therapy called T-DXd (Enhertu). If you have progressed while on T-DXd and have not had more than three previous treatments for advanced cancer, you may be able to join.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.